| Emerging SARS-CoV-2 variants: a review of its mutations, its implications and vaccine efficacy S Ramesh, M Govindarajulu, RS Parise, L Neel, T Shankar, S Patel, ... Vaccines 9 (10), 1195, 2021 | 124 | 2021 |
| Nutraceutical based SIRT3 activators as therapeutic targets in Alzheimer's disease M Govindarajulu, S Ramesh, L Neel, M Fabbrini, M Buabeid, A Fujihashi, ... Neurochemistry International 144, 104958, 2021 | 26 | 2021 |
| GC-MS and GC-IR analysis of regioisomeric cannabinoids related to 1-(5-fluoropentyl)-3-(1-naphthoyl)-indole J DeRuiter, F Smith, Y Abiedalla, L Neel, CR Clark Forensic Chemistry 10, 48-57, 2018 | 11 | 2018 |
| Structural alterations of the “address” moiety of NAN leading to the discovery of a novel opioid receptor modulator with reduced hERG toxicity H Ma, PP Pagare, M Li, LT Neel, RE Mendez, JC Gillespie, DL Stevens, ... Journal of medicinal chemistry 66 (1), 577-595, 2022 | 7 | 2022 |
| Spectroscopic differentiation and chromatographic separation of regioisomeric indole aldehydes: synthetic cannabinoids precursors Y Abiedalla, LW Smith, KM Abdel-Hay, L Neel, TS Belal, ... Forensic Chemistry 12, 78-90, 2019 | 6 | 2019 |
| Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics RL Cullum, LM Lucas, JI Senfeld, JT Piazza, LT Neel, K Whig, L Zhai, ... Plos one 15 (12), e0243901, 2020 | 4 | 2020 |
| GC–MS and GC–IR Analyses of the Methoxy-1-n-pentyl-3-(1-naphthoyl)-indoles: Regioisomeric Designer Cannabinoids A Thaxton-Weissenfluh, TS Belal, J DeRuiter, F Smith, Y Abiedalla, L Neel, ... Journal of chromatographic science 56 (9), 779-788, 2018 | 3 | 2018 |
| Computational Modeling, Design and Synthesis of Selective Cannabinoid Receptor 2 (CB2) Agonists LT Neel Auburn University, 2021 | | 2021 |
| Abstract A19: Discovery and characterization of selective and nonselective inhibitors of ErbB4 signaling: Putative targeted melanoma therapeutics LM Lucas, RL Cullum, JI Senfeld, LJ Cook, MH Harris, DZ Kaufmann, ... Cancer Research 80 (19_Supplement), A19-A19, 2020 | | 2020 |
| Discovery and characterization of selective and nonselective inhibitors of ErbB4 signaling: Putative targeted melanoma therapeutics. LM Lucas, RL Cullum, JI Senfeld, LJ Cook, MH Harris, DZ Kaufmann, ... CANCER RESEARCH 80 (19), 40-41, 2020 | | 2020 |
| Abstract A159: Characterization of putative ErbB4 antagonists: targeted melanoma drug discovery RL Cullum, LM Lucas, JT Piazza, JI Senfeld, LT Neel, RB Gupta, ... Molecular Cancer Therapeutics 17 (1_Supplement), A159-A159, 2018 | | 2018 |
| Screening methodologies for the discovery of small molecule melanoma therapeutics targeted at the ErbB4 receptor tyrosine kinase RL Cullum, JT Piazza, JI Senfeld, LT Neel, RB Gupta, AE David, DJ Riese Cancer Research 77 (13_Supplement), 1245-1245, 2017 | | 2017 |
Jack DeRuiterAuburn University在 auburn.edu 的电子邮件经过验证
